Genes May Predict Response to Diabetes Drug

The findings might be clinically relevant in the prediction of patients who will respond best to rosiglitazone treatment. Type 2 diabetics who have certain adiponectin polymorphisms appear to have less improvement in glucose control in response to rosiglitazone

Dr. Eun Seok Kang, lead investigator said that, "We found that variations in the adiponectin gene could affect the rosiglitazone treatment response to the serum adiponectin level and blood glucose control."

Dr. Kang of Yonsei University School of Medicine, Seoul and colleagues studied 166 patients with type 2 diabetes who were treated with rosiglitazone 4 mg per day for 12 weeks.

Compared with patients with other genotypes, carriers of the GG genotype of the single nucleotide polymorphism (SNP) 45 of the adiponectin gene had a smaller reduction in fasting plasma glucose levels and HbA1c values. There also was a significantly smaller increase in serum adiponectin concentration in this group.

In addition, carriers of the GG genotype of SNP276 showed less reduction in fasting glucose levels than did other patients.
Overall, those with the GG homozygote haplotype showed less response than did patients with other haplotypes.
Thus, concluded Dr. Kang, "these findings might be clinically relevant in the prediction of patients who will respond best to rosiglitazone treatment."
Diabetes Care 2005;28:1139-1144.

================================

Advertisement
At Advantage/OMC it is our mission to make your job easier by providing your patients with services and products of the highest quality.

We are a full service mail order pharmacy that can offer your patients a full line of prescription medications, blood glucose monitors and supplies, insulin pumps and supplies, as well as impotence devices. The Advantage/OMC alliance provides Major Medical Insurances through Advantage while OMC deals with Medicare Insurance.
https://www.diabetesincontrol.com/ads/omc/dest.php